Upadacitinib vs adalimumab in patients with rheumatoid arthritis and a prior inadequate response or intolerance to a tumour necrosis factor inhibitor: 12-week results from the randomised, double-blind, SELECT-SWITCH study
Annals of the Rheumatic Diseases · 2026-07 · 85 (7) · 1240-1254
DOI: 10.1016/j.ard.2026.03.013 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Annals of the Rheumatic Diseases, 2026-07. Verfasst von Eduardo Mysler und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Organización Medica de Investigación, Buenos Aires, Argentina. Electronic address: e.mysler@omiargentina.com.ar. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Adalimumab, Antirheumatic Agents, Heterocyclic Compounds, 3-Ring. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AbbVie Inc.
Abstract (Originalsprache)
OBJECTIVES: After the first tumour necrosis factor inhibitor (TNFi) failure, patients with rheumatoid arthritis (RA) often cycle to a second; however, switching mechanisms of action has been postulated to improve outcomes. The ongoing SELECT-SWITCH trial compared upadacitinib with adalimumab for active RA after first TNFi failure at 12 weeks. METHODS: Patients with inadequate response or intolerance to 1 nonadalimumab TNFi receiving stable methotrexate were randomised (1:1) to 15 mg once daily upadacitinib or 40 mg every-other-weekly adalimumab. The primary endpoint was achieving superiority in Disease Activity Score 28 (DAS28)-C-reactive protein (CRP) ≤3.2 at week 12. Ranked secondary endpoints (week 12, superiority) were (1) achieving ≥50% improvement in American College of Rheumatology response criteria (ACR50); (2) achieving DAS28-CRP
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology, Organización Medica de Investigación, Buenos Aires, Argentina. Electronic address: e.mysler@omiargentina.com.ar.
- Rheumatology and Clinical Immunology, University of Crete Medical School and "Institute of Molecular Biology and Biotechnology", Foundation for Research and Technology Hellas (FORTH), Heraklion, Greece.
- Department of Internal Medicine and Rheumatology, Sf. Maria Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
- Rheumatological-Immunological Medical Practice, Templin, Germany.
- Division of Rheumatology, Hospital de Clínicas de Porto Alegre/Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil.
- Division of Rheumatology, University of California, Los Angeles, CA, USA.
Förderung
- AbbVie Inc
Zitieren
APA
Mysler, E., Sidiropoulos, P. I., Balanescu, A., Detert, J., Xavier, R. M., Charles-Schoeman, C., Bessette, L., Crowley, A., Kaneko, Y., Zhang, Z., Nagy, O., Liu, Y., Ren, J., Romero, A. B., Suboticki, J. L., DeMasi, R., Meerwein, S., Fleischmann, R., & SELECT-SWITCH Study Investigators (2026). Upadacitinib vs adalimumab in patients with rheumatoid arthritis and a prior inadequate response or intolerance to a tumour necrosis factor inhibitor: 12-week results from the randomised, double-blind, SELECT-SWITCH study. Annals of the Rheumatic Diseases, 85(7), 1240-1254. https://doi.org/10.1016/j.ard.2026.03.013
Vancouver
Mysler E, Sidiropoulos PI, Balanescu A, Detert J, Xavier RM, Charles-Schoeman C, et al. Upadacitinib vs adalimumab in patients with rheumatoid arthritis and a prior inadequate response or intolerance to a tumour necrosis factor inhibitor: 12-week results from the randomised, double-blind, SELECT-SWITCH study. Annals of the Rheumatic Diseases. 2026;85(7):1240-1254. doi:10.1016/j.ard.2026.03.013
BibTeX
@article{Mysler2026,
author = {Mysler, Eduardo and Sidiropoulos, Prodromos I and Balanescu, Andra and Detert, Jacqueline and Xavier, Ricardo M and Charles-Schoeman, Christina and Bessette, Louis and Crowley, Angela and Kaneko, Yuko and Zhang, Zhuoli and Nagy, Orsolya and Liu, Yanxi and Ren, Jingchen and Romero, Ana B and Suboticki, Jessica L and DeMasi, Ryan and Meerwein, Sebastian and Fleischmann, Roy and SELECT-SWITCH Study Investigators, SELECT-SWITCH Study Investigators},
title = {Upadacitinib vs adalimumab in patients with rheumatoid arthritis and a prior inadequate response or intolerance to a tumour necrosis factor inhibitor: 12-week results from the randomised, double-blind, SELECT-SWITCH study},
journal = {Annals of the Rheumatic Diseases},
year = {2026},
volume = {85},
number = {7},
pages = {1240--1254},
doi = {10.1016/j.ard.2026.03.013}
}
EUVIMED